JP2005539023A5 - - Google Patents

Download PDF

Info

Publication number
JP2005539023A5
JP2005539023A5 JP2004527531A JP2004527531A JP2005539023A5 JP 2005539023 A5 JP2005539023 A5 JP 2005539023A5 JP 2004527531 A JP2004527531 A JP 2004527531A JP 2004527531 A JP2004527531 A JP 2004527531A JP 2005539023 A5 JP2005539023 A5 JP 2005539023A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hydrocarbyl
group
halo
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004527531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005539023A (ja
Filing date
Publication date
Priority claimed from US10/213,793 external-priority patent/US20030100594A1/en
Application filed filed Critical
Publication of JP2005539023A publication Critical patent/JP2005539023A/ja
Publication of JP2005539023A5 publication Critical patent/JP2005539023A5/ja
Withdrawn legal-status Critical Current

Links

JP2004527531A 2002-08-07 2003-02-14 炭酸脱水酵素媒介疾患の治療方法 Withdrawn JP2005539023A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/213,793 US20030100594A1 (en) 2001-08-10 2002-08-07 Carbonic anhydrase inhibitor
PCT/US2003/004494 WO2004014352A2 (en) 2002-08-07 2003-02-14 Methods for treating carbonic anhydrase mediated disorders

Publications (2)

Publication Number Publication Date
JP2005539023A JP2005539023A (ja) 2005-12-22
JP2005539023A5 true JP2005539023A5 (cg-RX-API-DMAC10.html) 2006-03-30

Family

ID=31714232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004527531A Withdrawn JP2005539023A (ja) 2002-08-07 2003-02-14 炭酸脱水酵素媒介疾患の治療方法
JP2004527530A Withdrawn JP2005539022A (ja) 2002-08-07 2003-02-14 悪性腫瘍の治療のためのシクロオキシゲナーゼ−2選択的阻害剤及びカルボニックアンヒドラーゼ阻害剤の組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004527530A Withdrawn JP2005539022A (ja) 2002-08-07 2003-02-14 悪性腫瘍の治療のためのシクロオキシゲナーゼ−2選択的阻害剤及びカルボニックアンヒドラーゼ阻害剤の組成物

Country Status (12)

Country Link
US (2) US20030100594A1 (cg-RX-API-DMAC10.html)
EP (2) EP1526895A2 (cg-RX-API-DMAC10.html)
JP (2) JP2005539023A (cg-RX-API-DMAC10.html)
KR (1) KR20050056189A (cg-RX-API-DMAC10.html)
CN (1) CN1681557A (cg-RX-API-DMAC10.html)
AU (2) AU2003213062A1 (cg-RX-API-DMAC10.html)
BR (2) BR0313299A (cg-RX-API-DMAC10.html)
CA (2) CA2495516A1 (cg-RX-API-DMAC10.html)
IL (1) IL166685A0 (cg-RX-API-DMAC10.html)
MX (2) MXPA05001496A (cg-RX-API-DMAC10.html)
PL (1) PL374994A1 (cg-RX-API-DMAC10.html)
WO (2) WO2004014430A1 (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946243B2 (en) * 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US20100135980A1 (en) * 2000-10-16 2010-06-03 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging, disorders of aging, cancer, as growth factors, and as an alternative to stem cell therapy
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
ES2436524T3 (es) 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
WO2005079781A1 (en) * 2004-02-25 2005-09-01 La Trobe University Therapeutic and/or prophylactic method
WO2005094815A1 (en) * 2004-03-30 2005-10-13 Amorepacific Corporation Dual inhibition of cyclooxygenase-2 and carbonic anhydrase
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CA2609185A1 (en) 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
JP4872076B2 (ja) * 2005-09-15 2012-02-08 国立大学法人 長崎大学 硝子体可視化剤
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008075148A2 (en) * 2006-12-15 2008-06-26 Pfizer Products Inc. Tricyclic inhibitors of carbonic anhydrase
CA2711678A1 (en) * 2008-01-09 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
AU2009322167B2 (en) 2008-12-05 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
WO2010125004A1 (en) * 2009-04-29 2010-11-04 Nerviano Medical Sciences S.R.L. Cdk inhibitor salts
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
CN102574782B (zh) * 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
CN103221388B (zh) * 2010-07-09 2016-09-28 维理生物技术公司 用于抑制转移性肿瘤生长的新型磺酰胺化合物
BR112013008527A2 (pt) * 2010-12-17 2016-07-12 Nerviano Medical Sciences Srl derivados de pirazolo-quinazolina substituídos como inibidores de cinase
CN102351793B (zh) * 2011-08-30 2013-11-06 江苏正大清江制药有限公司 4-[3-(4-甲基苯基)-5-(三氟甲基)-1-氢-吡唑-1-基]苯磺酰胺的直接合成方法
EP2757886A1 (de) 2011-09-23 2014-07-30 Bayer Intellectual Property GmbH Verwendung 4-substituierter 1-phenyl-pyrazol-3-carbonsäurederivate als wirkstoffe gegen abiotischen pflanzenstress
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
HUE035739T2 (en) 2013-01-14 2018-05-28 Molecular Insight Pharm Inc Triazine-based radiopharmaceuticals and radiological imaging agents
US10391119B2 (en) * 2015-12-22 2019-08-27 Nof Corporation Lacrimal oily layer stabilizer and eye drops comprising same
WO2018211474A1 (en) 2017-05-19 2018-11-22 Trudell Medical International Positive expiratory pressure device
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN109557309B (zh) * 2018-12-04 2021-09-10 九江学院附属医院 碳酸酐酶-2作为检测标记物在肾结石诊断方面的应用
CN111233786B (zh) * 2020-02-04 2021-11-26 中国人民解放军军事科学院军事医学研究院 含五元杂环的苯磺酰胺类化合物及其制备方法和用途
CN115607567A (zh) * 2022-09-28 2023-01-17 长春工业大学 一种环保型改善心肌缺血的血液透析液

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582619A (en) * 1977-05-14 1981-01-14 Centrala Ind Medicamente Medicinal compositions for the treatment of gastritis gastro-duodenitis and duodenal ulcers
US5095026A (en) * 1983-02-04 1992-03-10 University Of Iowa Research Foundation Prodrugs of carbonic anhydrase inhibitors
US5157044A (en) * 1983-02-04 1992-10-20 University Of Iowa Research Foundation Analogs of carbonic anhydrase inhibitors and their use as topical IOP inhibitors
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
AU653279B2 (en) * 1991-12-30 1994-09-22 Sanofi Novel 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
CA2277954A1 (en) * 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JP3267300B2 (ja) * 1995-02-13 2002-03-18 ジー.ディー.サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
US5944021A (en) * 1995-06-07 1999-08-31 Rodriguez; Victorio C. Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema
DE19600721A1 (de) * 1996-01-12 1997-07-17 Hoechst Ag Verwendung von Inhibitoren des Carboanhydratase (CAH) zum Herstellen eines Medikaments zur Behandlung von Krebs
TR199801665T2 (xx) * 1996-02-26 1998-12-21 Advanced Research & Technology Institute Makular �demin engellenmesi i�in karbonik anhidraz inhibit�rlerinin kullan�m�.
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
CA2372912C (en) * 1997-10-14 2008-12-02 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US5972684A (en) * 1997-11-25 1999-10-26 Incyte Pharmaceuticals, Inc. Carbonic anhydrase VIII
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.
WO2000018741A2 (en) * 1998-09-30 2000-04-06 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds as cox-2 inhibitors
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
ES2273688T3 (es) * 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
WO2001028548A1 (en) * 1999-10-19 2001-04-26 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
PT1274700E (pt) * 2000-01-03 2005-02-28 Pharmacia Corp Di-hidrobenzopiranos di-hidrobenzotiopiranos e tetra-hidroquinolinas para o tratamento de afeccoes mediadas por cox-2
JP2003531824A (ja) * 2000-02-01 2003-10-28 ケイマン ケミカル カムパニー,インク. フルプロステノールおよび関連プロスタグランジンF2α類似体の内部1,15−ラクトン、ならびに緑内障および眼高血圧の治療におけるそれらの使用
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
JP2002179657A (ja) * 2000-05-26 2002-06-26 Japan Tobacco Inc 5−(4−アミノスルホニル−3−フルオロフェニル)−4−シクロヘキシル−2−メチルオキサゾールの結晶多形
US20020009421A1 (en) * 2000-06-01 2002-01-24 Wilder Karol J. Therapy following skin injury from exposure to ultraviolet radiation
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1299123A2 (en) * 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
WO2002013800A2 (en) * 2000-08-11 2002-02-21 Einar Stefansson Method for the prevention and treatment of retinopathy
SE0004229D0 (sv) * 2000-11-17 2000-11-17 Aga Ab Inhalation of nitric oxide
CA2456939A1 (en) * 2001-08-10 2003-02-20 Pharmacia Corporation Carbonic anhydrase inhibitors

Similar Documents

Publication Publication Date Title
ES2243978T3 (es) Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
US6342510B1 (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
ES2262156T3 (es) Composicion que comprende un inhibidor de la ciclooxigenasa 2 y un inhibidor de la leucotrieno a4 hidrolasa.
US6136839A (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
EP0888127B1 (en) Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
ES2252448T3 (es) Composicion parenteral reconstituible que contiene un inhibidor de la cox-2.
CA2495502A1 (en) Methods for treating carbonic anhydrase mediated disorders
EP0880363B1 (en) Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a 4 hydrolase inhibitor
JP2004526765A5 (cg-RX-API-DMAC10.html)
NZ500141A (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
US20030157061A1 (en) Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
RU2004121147A (ru) Применение ингибиторов сох-2 в сочетании с противовирусными агентами для лечения инфекции вируса папилломы
JP2005501850A5 (cg-RX-API-DMAC10.html)
JP2005507871A5 (cg-RX-API-DMAC10.html)
CA2414674A1 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
US20020035156A1 (en) Combination therapy in the prevention of cardiovascular disorders
JP2005501083A5 (cg-RX-API-DMAC10.html)
JP2008533109A (ja) 利尿を促進するための複合治療
JP2001521889A5 (cg-RX-API-DMAC10.html)
JP2005535657A5 (cg-RX-API-DMAC10.html)
HK1093011A (en) Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist
MXPA99009495A (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders